Molecular Pharmaceutics
Brief Article
(3) Chourasia, M. K.; Jain, S. K. Pharmaceutical approaches to colon
targeted drug delivery systems. J. Pharm. Pharm. Sci. 2003, 6 (1), 33−
66.
(4) Jung, Y. J.; Lee, J. S.; Kim, Y. M. Colon-specific prodrugs of 5-
aminosalicylic acid: synthesis and in vitro/in vivo properties of acidic
amino acid derivatives of 5-aminosalicylic acid. J. Pharm. Sci. 2001, 90
(11), 1767−75.
(5) Davaran, S.; Hanaee, J.; Khosravi, A. Release of 5-amino salicylic
acid from acrylic type polymeric prodrugs designed for colon-specific
drug delivery. J. Controlled Release 1999, 58 (3), 279−87.
(6) Wiwattanapatapee, R.; Lomlim, L.; Saramunee, K. Dendrimers
conjugates for colonic delivery of 5-aminosalicylic acid. J. Controlled
Release 2003, 88 (1), 1−9.
(7) Ahmad, S.; Tester, R. F.; Corbett, A.; Karkalas, J. Dextran and 5-
aminosalicylic acid (5-ASA) conjugates: synthesis, characterization and
enzymic hydrolysis. Carbohydr. Res. 2006, 341 (16), 2694−2701.
(8) Zou, M.; Okamoto, H.; Cheng, G.; Hao, X.; Sun, J.; Cui, F.;
Danjo, K. Synthesis and properties of polysaccharide prodrugs of 5-
aminosalicylic acid as potential colon-specific delivery systems. Eur. J.
Pharm. Biopharm. 2005, 59 (1), 155−60.
(9) Kesisoglou, F.; Zhou Simon, Y.; Niemiec, S.; Lee Jordan, W.;
Zimmermann Ellen, M.; Fleisher, D. Liposomal formulations of
inflammatory bowel disease drugs: local versus systemic drug delivery
in a rat model. Pharm. Res. 2005, 22 (8), 1320−30.
(10) Huttunen, K. M.; Mahonen, N.; Leppanen, J.; Vepsalainen, J.;
Juvonen, R. O.; Raunio, H.; Kumpulainen, H.; Jarvinen, T.; Rautio, J.
Novel cyclic phosphate prodrug approach for cytochrome P450-
activated drugs containing an alcohol functionality. Pharm. Res. 2007,
24 (4), 679−87.
(11) Sun, W.; Peng, W.; Li, G.; Jiang, T. Design, synthesis, and
sustained-release property of 1,3-cyclic propanyl phosphate ester of
18(beta)-glycyrrhetinic acid. Chem. Biol. Drug Des. 2011, 77 (3), 206−
211.
(12) Erion, M. D. Prodrugs for Liver-targeted Drug Delivery. In
Prodrugs: Challenges and Rewards, Part 1, 1st ed.; Stella, V. J.,
Borchardt, R. T., Hageman, M. J., Oliyai, R., Maag, H., Tilley, J. W.,
Eds.; Springer Science + Business Media: New York, 2007; pp 541−
72.
(19) Pelkonen, O.; Maenpaa, J.; Taavitsainen, P.; Rautio, A.; Raunio,
H. Inhibition and induction of human cytochrome P450 (CYP)
enzymes. Xenobiotica 1998, 28 (12), 1203−1253.
(20) Bergheim, I.; Bode, C.; Parlesak, A. Distribution of cytochrome
P450 2C, 2E1, 3A4, and 3A5 in human colon mucosa. BMC Clin.
Pharmacol. 2005, 5, 4.
(21) Gervot, L.; Carriere, V.; Costet, P.; Cugnenc, P.-H.; Berger, A.;
Beaune, P.; de Waziers, I. CYP3A5 is the major cytochrome P450 3A
expressed in human colon and colonic cell lines. Environ. Toxicol.
Pharmacol. 1996, 2 (4), 381−388.
(22) Paine, M. F.; Hart, H. L.; Ludington, S. S.; Haining, R. L.; Rettie,
A. E.; Zeldin, D. C. The human intestinal cytochrome P450 “pie”.
Drug Metab. Dispos. 2006, 34 (5), 880−6.
(23) Gonzalez, F. J.; Tukey, R. H. Drug Metabolism. In Goodman and
Gilman’s The Pharmacological Basis of Therapeutics; Brunton, L. L.,
Lazo, J. S., Parker, K. L., Eds.; The McGraw-Hill Companies, Inc.:
New York, 2006; pp 71−91.
(24) Testa, B.; Kramer, S. D. The biochemistry of drug metabolism–
an introduction: Part 2. Redox reactions and their enzymes. Chem.
Biodiversity 2007, 4 (3), 257−405.
(25) Khor, B.; Gardet, A.; Xavier, R. J. Genetics and pathogenesis of
inflammatory bowel disease. Nature 2011, 474 (7351), 307−17.
(26) Nakano, T.; Inoue, I.; Alpers, D. H.; Akiba, Y.; Katayama, S.;
Shinozaki, R.; Kaunitz, J. D.; Ohshima, S.; Akita, M.; Takahashi, S.;
Koyama, I.; Matsushita, M.; Komoda, T. Role of lysophosphatidylcho-
line in brush-border intestinal alkaline phosphatase release and
restoration. Am. J. Physiol. 2009, 297 (1), G207−14.
(27) Pastorini, E.; Locatelli, M.; Simoni, P.; Roda, G.; Roda, E.; Roda,
A. Development and validation of a HPLC-ESI-MS/MS method for
the determination of 5-aminosalicylic acid and its major metabolite N-
acetyl-5-aminosalicylic acid in human plasma. J. Chromatogr., B: Anal.
Technol. Biomed. Life Sci. 2008, 872 (1−2), 99−106.
(28) Krise, J. P.; Stella, V. J. Prodrugs of phosphates, phosphonates,
and phosphinates. Adv. Drug Delivery Rev. 1996, 19 (2), 287−310.
(13) Mu, F.; Coffing, S. L.; Riese, D. J., 2nd; Geahlen, R. L.; Verdier-
Pinard, P.; Hamel, T. E.; Johnson, J.; Cushman, M. Design, synthesis,
and biological evaluation of a series of lavendustin A analogues that
inhibit EGFR and Syk tyrosine kinases, as well as tubulin
polymerization. J. Med. Chem. 2001, 44 (3), 441−52.
(14) Erion, M. D.; Reddy, K. R.; Boyer, S. H.; Matelich, M. C.;
Gomez-Galeno, J.; Lemus, R. H.; Ugarkar, B. G.; Colby, T. J.;
Schanzer, J.; Van Poelje, P. D. Design, synthesis, and characterization
of a series of cytochrome P(450) 3A-activated prodrugs (HepDirect
prodrugs) useful for targeting phosph(on)ate-based drugs to the liver.
J. Am. Chem. Soc. 2004, 126 (16), 5154−63.
(15) Boyer, S. H.; Sun, Z.; Jiang, H.; Esterbrook, J.; Gomez-Galeno, J.
E.; Craigo, W.; Reddy, K. R.; Ugarkar, B. G.; MacKenna, D. A.; Erion,
M. D. Synthesis and characterization of a novel liver-targeted prodrug
of cytosine-1-beta-D-arabinofuranoside monophosphate for the treat-
ment of hepatocellular carcinoma. J. Med. Chem. 2006, 49 (26), 7711−
20.
(16) Reddy, K. R.; Matelich, M. C.; Ugarkar, B. G.; Gomez-Galeno, J.
E.; DaRe, J.; Ollis, K.; Sun, Z.; Craigo, W.; Colby, T. J.; Fujitaki, J. M.;
Boyer, S. H.; van Poelje, P. D.; Erion, M. D. Pradefovir: a prodrug that
targets adefovir to the liver for the treatment of hepatitis B. J. Med.
Chem. 2008, 51 (3), 666−76.
(17) Liang, Y.; Narayanasamy, J.; Schinazi, R. F.; Chu, C. K.
Phosphoramidate and phosphate prodrugs of (-)-beta-D-(2R,4R)-
dioxolane-thymine: synthesis, anti-HIV activity and stability studies.
Bioorg. Med. Chem. 2006, 14 (7), 2178−89.
(18) Kim, J.; De Castro, K. A.; Lim, M.; Rhee, H. Reduction of
aromatic and aliphatic keto esters using sodium borohydride/MeOH
at room temperature: a thorough investigation. Tetrahedron 2010, 66
(23), 3995−4001.
F
dx.doi.org/10.1021/mp300330v | Mol. Pharmaceutics XXXX, XXX, XXX−XXX